首页> 外文期刊>Cancer science. >Expression of classical human leukocyte antigen class I antigens, HLA‐E and HLA‐G, is adversely prognostic in pancreatic cancer patients
【24h】

Expression of classical human leukocyte antigen class I antigens, HLA‐E and HLA‐G, is adversely prognostic in pancreatic cancer patients

机译:古典人白细胞抗原等级I抗原,HLA-E和HLA-G的表达在胰腺癌患者中对胰腺癌患者不利预后

获取原文
获取外文期刊封面目录资料

摘要

The expression of classical human leukocyte antigen class I antigens (HLA‐I) on the surfaces of cancer cells allows cytotoxic T cells to recognize and eliminate these cells. Reduction or loss of HLA‐I is a mechanism of escape from antitumor immunity. The present study aimed to investigate the clinicopathological impacts of HLA‐I and non–classical HLA‐I antigens expressed on pancreatic ductal adenocarcinoma (PDAC) cells. We performed immunohistochemistry to detect expression of HLA‐I antigens in PDAC using 243 PDAC cases and examined their clinicopathological influences. We also investigated the expression of immune‐related genes to characterize PDAC tumor microenvironments. Lower expression of HLA‐I, found in 33% of PDAC cases, was significantly associated with longer overall survival. Higher expression of both HLA‐E and HLA‐G was significantly associated with shorter survival. Multivariate analyses revealed that higher expression of these three HLA‐I antigens was significantly correlated with shorter survival. Higher HLA‐I expression on PDAC cells was significantly correlated with higher expression of IFNG , which also correlated with PD1 , PD‐L1 and PD‐L2 expression. In?vitro assay revealed that interferon gamma (IFNγ) stimulation increased surface expression of HLA‐I in three PDAC cell lines. It also upregulated surface expression of HLA‐E, HLA‐G and immune checkpoint molecules, including PD‐L1 and PD‐L2. These results suggest that the higher expression of HLA‐I, HLA‐E and HLA‐G on PDAC cells is an unfavorable prognosticator. It is possible that IFNγ promotes a tolerant microenvironment by inducing immune checkpoint molecules in PDAC tissues with higher HLA‐I expression on PDAC cells.
机译:古典人白细胞抗原等级I抗原(HLA-1)在癌细胞表面上的表达允许细胞毒性T细胞识别和消除这些细胞。 HLA-I的减少或丧失是逃离抗肿瘤免疫的机制。本研究旨在研究HLA-I和非古典HLA-I抗原在胰腺导管腺癌(PDAC)细胞上表达的临床病理学影响。我们使用243个PDAC病例进行免疫组化以检测PDAC中HLA-I抗原的表达,并检查其临床病理影响。我们还研究了免疫相关基因的表达,以表征PDAC肿瘤微环境。 HLA-I的表达,在33%的PDAC病例中发现,与较长的整体存活率显着相关。 HLA-E和HLA-G的更高表达与较短的存活率显着相关。多变量分析表明,这三种HLA-1抗原的表达更高,与较短的存活率显着相关。在PDAC细胞上表达较高的HLA-I表达与IFNG的更高表达显着相关,其也与PD1,PD-L1和PD-L2表达相关。在体外测定中显示出干扰素γ(IFNγ)刺激在三种PDAC细胞系中的HLA-1的表面表达增加。它还上调HLA-E,HLA-G和免疫检查点分子的表面表达,包括PD-L1和PD-L2。这些结果表明,在PDAC细胞上的HLA-1,HLA-E和HLA-G的较高表达是一种不利的预测器。 IFNγ可能通过在PDAC细胞上诱导PDAC组织中的免疫检查点分子来促进耐受性微环境。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号